oncology II Flashcards
selective estrogen receptor modulatorsm
- SERMs
tamoxifen
soltamox
- SERMs
tamoxifen info:
- increase risk of uterine or endometrial cancer
- QT prolongations
- increase risk of thromboembolic event
- hypo K and Mg
- hot flashes/ night sweats etc.
- decreases bone density… supplement w/ Ca and vitamin D
- teratogenic
fulvestrant
Faslodex
IM only
- selective estrogen receptor degrader (SERD)
anastrozole
Arimidex
- aromatase inhibitor
letrozole
Femara
- aromatase inhibitor
exemestane
Aromasin
- aromatase inhibitor
trastuzumab
Herceptin
need HER2 positive
- mab
gonadotropin-releasing hormone agonist
GnRH agonists
also known as luteinizing hormone-releasing hormone (LHRH) agonists, they reduce testosterone through a negative feedback mechanism, causing an initial surge in test followed by gradual reduction
- will cause decrease in bone density, sue w/ Ca and vitamin D
- tumor flare: prevent w/ concurrent sue of antiandrogent
leuprolide
Lupron Depot
- GnRH agonists
Goserelin
Zoladex
- GnRH agonists
GnRH antagonists
block GnRH directly causing a rapid decrease in testosterone productions
degarelix
firmagon
- GnRH antagonists
Relugolix
Orgovyx
- GnRH antagonists
bicalutamide
Casodex
- first gen, antiandrogens
Nilutamide
Niladron
- night blindness, DISULFIRAM reactions (avoid OH)
- first gen, antiandrogens
apalutamide
erleada
- seizures risk and QT prolongation
- second gen, antiandrogens
darolutamide
Nabeqa
- neutropenia
- second gen, antiandrogens
enzalutamide
Xtandi
- seizures risk
- second gen, antiandrogens
Abiraterone
Zytiga
- androgen biosynthesis inhibitors
BSA (m^2)
= sq root of ((Ht(cm) x Wt(kg))/ 3600)
Cyclophosphamide
Ifosfamide
Ifex
- dispensed w/ Mesna
- alkylating agents
carmustine
BiCNU, Gliadel Wafer)
- alkylating agents
Lomustine
Gleostine
- alkylating agents
Busulfan
Myleran
- alkylating agents
Cisplatin
- platinum-based compounds
Carboplatin
- platinum-based compounds
oxaliplatin
- platinum-based compounds
Doxorubicin
adriamycin
keep track of lifetime accumulation of dose
450-550 max, totect when >300 cumulative dose
- anthracyclines
Mitoxantrone
- anthracyclines
Irinotecan
Camptosar
- topoisomerase I inhibitors
Bleomycin
- topoisomerase II inhibitors
etoposide
- topoisomerase II inhibitors
vincristine
- vinca alkaloids
vinblastine
- vinca alkaloids
paclitaxel
- taxanes
docetaxel
- taxanes
fluorouracil
“5-FU”
- pyrimidine analog antimetabolites
capecitabine
Xeloda
- pyrimidine analog antimetabolites
methotrexate
trexall, otrexup, rasuva
- folate antimetabolites
pemetrexed
alimta
- folate antimetabolites
pralatrexate
folotyn
- folate antimetabolites
in autoimmune disease
folate
- dose of methotrexate is much lower
- folic acid is recommend prophylactically to reduce SE
- leucovorin is NOT used unless the pt does not respond to folic acid
in oncological disease
folate
- dose of methotrexate is much higher
- rescue the pt from high- dose tox, a reduced form of folate must be started after methotrexate has a chance to kill the chance cancer cells. Leucovorin or levoleucovorin is given
- regular folate is not effective in rescue
- folate is sued w/ pemetrexed and pralatrexate to reduce SE
ci
circulatory system
- moncolonal antiboides
tu
tumor
- moncolonal antiboides
li
immune system
- moncolonal antiboides
bevacizumab
Avastin
impairs wound healing: do not administer 28 days before or after surgery
- vascular endothelial growth (VEGF) inhibitors
trastuzumab
Herceptin
need HER2 positive before start
monitor LVEF
- human epidermal growth factor 2 (HER2) inhibitor
cetuximab
Erbitux
- epidermal growth factor preceptor (EGFR) inhibitors
rituximab
Rituxan
- leukocyte cluster of differentiation (CD) antigens inhibitors
pembrolizumab
keytruda
- programmed death receiptor-1 (PD-1) inhibitor
ipilimumab
yervoy
- CTLA-4 inhibitor
cytotoxic T-lymphocyte antigen-4
imatinib
gleevec
- tyrosin kinase inhibitors